...
机译:一线克里齐齐替尼与Alk阳性肺癌的化疗
Department of Medical Oncology Peter MacCallum Cancer Centre St. Andrew's Pl.East Melbourne VIC;
State Key Laboratory of South China Hong Kong Cancer Institute Chinese University of Hong;
Seoul National University HospitalSeoul South Korea;
Guangdong Lung Cancer InstituteGuangzhou China;
Kinki UniversityOsaka Japan;
Florida Hospital Cancer InstituteOrlando United States;
Vall D'Hebron Institute of Oncology Vall D'Hebron University HospitalBarcelona Spain;
Istituto Toscano TumoriLivorno Italy;
Pfizer OncologyMilan Italy;
Pfizer OncologyMilan Italy;
Pfizer Oncology United States;
Pfizer Global Innovative Pharma BusinessNew York United States;
Pfizer OncologySan Diego CA United States;
Pfizer OncologyMilan Italy;
Christie Hospital and Institute of Cancer Sciences Manchester UniversityManchester United Kingdom;
Angiotensin II receptor; Epidermal growth factor receptor; Mineralocorticoid receptor; Modifications; Receptor tyrosine kinases Signaling;
机译:一线克里齐齐替尼与Alk阳性肺癌的化疗
机译:克唑替尼与化疗对晚期ALK阳性非小细胞肺癌患者的颅内疗效:来自PROFILE 1014的结果
机译:克唑替尼与化学疗法治疗晚期ALK阳性肺癌
机译:培美曲塞与多西他赛单药化疗在未接受化疗的老年晚期非小细胞肺癌患者中的作用
机译:吉西他滨联合顺铂一线化疗对晚期胆道癌患者治疗效果的预测因素
机译:克唑替尼与化学疗法治疗ALK阳性晚期非小细胞肺癌亚洲患者
机译:Crizotinib与常规化疗在一线治疗中的ALK阳性非小细胞肺癌:系统审查和荟萃分析